Hemovent expands manufacturing facility for ECLS device serial production

Hemovent GmbH has completed the expansion of its manufacturing facility to accommodate serial production of its ECLS device. The company is on schedule to achieve its first-in-man milestone in the second half of 2018.

“We have completed the expansion of our manufacturing facility in order to accommodate serial production of our device and are well on schedule to achieve our first-in-man milestone in the second half of 2018.”biospace.com

• 1 source
• biospace.comHemovent Successfully Debuts ExtraCorporeal Life Support (ECLS) Device from its Artificial Lung Platform - BioSpaceHeather McKenzieOct 16, 2017

Summarized from public sources; check the original articles before acting on it.